Estados financieros detallados de INmune Bio, Inc. (INMB): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
INmune Bio, Inc. registró ingresos de $50000 en el último ejercicio fiscal, con un CAGR de 5 años del 35.4%.
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $2.05, INMB presenta beneficios negativos (P/E no significativo) y un ROE del -82.87%. La capitalización bursátil es de $54M.
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | $11000 | $181000 | $374000 | $155000 | $14000 | $50000 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 | $11000 | $181000 | $374000 | $155000 | $14000 | $50000 |
| I+D | $101495 | $435362 | $1.1M | $3.3M | $5.9M | $20.5M | $17.1M | $20.3M | $33.2M | $20.7M |
| Generales y Administrativos | $125996 | $546118 | $9.1M | $4.5M | $6.3M | $8.8M | $9.3M | $9.6M | $9.5M | $10.3M |
| Gastos Operativos | $227491 | $981480 | $12.4M | $7.8M | $12.2M | $29.3M | $26.3M | $29.9M | $42.6M | $30.9M |
| Beneficio Operativo | -$227000 | -$981000 | -$12.4M | -$7.8M | -$12.2M | -$29.2M | -$26.0M | -$29.7M | -$42.6M | -$30.9M |
| EBITDA | -$50000 | $149990 | 0 | -$7.7M | 0 | -$1.2M | -$1.3M | -$267000 | -$41.5M | -$45.8M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$277000 | -$831000 | -$12.4M | -$7.7M | -$12.1M | -$30.3M | -$27.3M | -$30.0M | -$42.1M | -$45.9M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$277000 | -$831000 | -$12.4M | -$7.7M | -$12.1M | -$30.3M | -$27.3M | -$30.0M | -$42.1M | -$45.9M |
| BPA | $-0.05 | $-0.07 | $-1.11 | $-0.89 | $-1.01 | $-1.88 | $-1.52 | $-1.67 | $-2.11 | $-1.86 |
| BPA Diluido | $-0.05 | $-0.07 | $-1.11 | $-0.89 | $-1.01 | $-1.88 | $-1.52 | $-1.67 | $-2.11 | $-1.86 |
| Acciones en Circulación (Diluidas) | $5.1M | $11.2M | $11.2M | $10.3M | $12.0M | $16.1M | $17.9M | $18.0M | $19.9M | $26.6M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | -$56000 | -$52000 | 0 |
| Beneficio Operativo | -$7.4M | -$5.5M | -$5.8M | -$1.5M |
| EBITDA | -$6.5M | -$5.2M | -$5.4M | -$1.2M |
| Beneficio Neto | -$6.5M | -$5.3M | -$5.4M | -$1.3M |
| BPA | $-0.24 | $-0.20 | $-0.20 | $-0.05 |
| BPA Diluido | $-0.24 | $-0.20 | $-0.20 | $-0.05 |
Balance (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $141659 | $1.4M | $186204 | $7.0M | $22.0M | $74.8M | $52.2M | $35.8M | $20.9M | $24.8M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | $327608 | $647586 | $645364 | 0 | $5.5M | $8.5M | $2.4M | $1.4M | $4.5M |
| Inventario | 0 | 0 | 0 | -$769.1M | 0 | -$5.5M | $34000 | 0 | 0 | 0 |
| Activos Corrientes | $451607 | $1.9M | $849342 | $7.8M | $24.0M | $82.6M | $64.7M | $39.9M | $22.7M | $29.9M |
| Inmovilizado Material | 0 | 0 | 0 | $191543 | $156000 | $726000 | $507000 | $414000 | $307000 | $914000 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | $16.5M | $16.5M | $16.5M | $16.5M | $16.5M | $16.5M | $16.5M | $16.5M | 0 |
| Activos Totales | $451607 | $18.4M | $17.4M | $24.5M | $40.7M | $99.9M | $81.8M | $57.0M | $39.6M | $32.4M |
| Cuentas por Pagar | $220810 | $136403 | $553221 | $401989 | $1.5M | $3.8M | $5.2M | $7.9M | $6.6M | $7.8M |
| Deuda a Corto | $350000 | 0 | 0 | 0 | 0 | 0 | $5.0M | $9.9M | 0 | 0 |
| Pasivos Corrientes | $600810 | $309717 | $823766 | $700379 | $1.8M | $4.4M | $10.9M | $18.5M | $7.2M | $8.4M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | $14.5M | $9.7M | 0 | 0 | 0 |
| Pasivos Totales | $600810 | $309717 | $823766 | $860543 | $1.9M | $19.7M | $21.7M | $18.9M | $7.5M | $8.8M |
| Reservas | -$326359 | -$1.2M | -$13.6M | -$21.3M | -$33.4M | -$63.7M | -$91.0M | -$121.0M | -$163.1M | -$209.0M |
| Patrimonio Neto | -$149203 | $18.1M | $16.5M | $23.6M | $38.8M | $80.2M | $60.1M | $38.1M | $32.1M | $23.5M |
| Deuda Total | $350000 | 0 | 0 | $168452 | $160000 | $15.2M | $15.3M | $10.4M | $384000 | $1.0M |
| Deuda Neta | $208341 | -$1.4M | -$186204 | -$6.8M | -$21.8M | -$59.6M | -$36.8M | -$25.4M | -$20.5M | -$23.7M |
| Capital Circulante | -$149203 | $1.6M | $25576 | $7.1M | $22.2M | $78.2M | $53.8M | $21.5M | $15.4M | $21.5M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $27.7M | $24.8M | $21.4M | $18.4M |
| Activos Totales | $33.4M | $32.4M | $25.8M | $26.8M |
| Pasivos Totales | $8.0M | $8.8M | $6.2M | $6.5M |
| Patrimonio Neto | $25.4M | $23.5M | $19.6M | $20.4M |
| Deuda Total | $1.1M | $1.0M | $1.5M | $1.4M |
Flujo de Caja (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$277491 | -$831486 | -$12.4M | -$7.7M | -$12.1M | -$30.3M | -$27.3M | -$30.0M | -$42.1M | -$45.9M |
| Amortizaciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $84000 |
| Compensación en Acciones | 0 | $199556 | $10.0M | $4.1M | 0 | $4.8M | $7.1M | $7.4M | $7.6M | $9.9M |
| Cambio en Capital Circulante | -$89888 | $20096 | $379670 | -$260881 | $43509 | -$3.1M | -$2.9M | $10.4M | $1.0M | -$2.5M |
| Flujo de Caja Operativo | -$317379 | -$761834 | -$2.1M | -$5.4M | -$8.9M | -$28.5M | -$22.7M | -$12.0M | -$33.4M | -$22.6M |
| Inversiones (CapEx) | 0 | -$100000 | 0 | 0 | -$4 | -$15.0M | 0 | 0 | 0 | -$1.0M |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | -$1.0M | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$317379 | -$861834 | -$2.1M | -$5.4M | -$8.9M | -$43.5M | -$22.7M | -$12.0M | -$33.4M | -$23.6M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$5.4M | -$3.0M | -$3.4M | -$3.2M |
| Inversiones (CapEx) | -$193000 | -$705999 | 0 | -$430000 |
| Flujo de Caja Libre | -$5.6M | -$3.7M | -$3.4M | -$3.6M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $3.0M | -$6.6M | $1.5M | $1.4M |
Crecimiento y Márgenes (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | | | | | +1545.5% | +106.6% | -58.6% | -91.0% | +257.1% |
| Crecimiento Beneficio Neto (anual) | | -200.0% | -1397.0% | +38.3% | -57.6% | -150.8% | +10.0% | -9.9% | -40.2% | -9.2% |
| Crecimiento BPA (anual) | | -36.7% | -1398.0% | +19.8% | -13.5% | -86.1% | +19.1% | -9.9% | -26.3% | +11.8% |
| Cambio en Acciones (anual) | | +119.6% | +0.0% | -8.4% | +16.7% | +34.6% | +11.1% | +0.3% | +10.9% | +33.3% |
| Crecimiento FCF (anual) | | -171.5% | -138.9% | -161.5% | -66.1% | -386.4% | +47.9% | +47.2% | -178.5% | +29.2% |
| Margen Bruto | | | | | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Margen Operativo | | | | | -111163.6% | -16106.6% | -6938.8% | -19187.7% | -304535.7% | -61738.0% |
| Margen EBITDA | | | | | 0.0% | -655.8% | -360.4% | -172.3% | -296635.7% | -91698.0% |
| Margen Neto | | | | | -109990.9% | -16762.4% | -7299.2% | -19360.0% | -300585.7% | -91866.0% |
| Margen FCF | | | | | -81305.9% | -24035.4% | -6065.8% | -7729.0% | -238292.9% | -47248.0% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.06 | $-0.08 | $-0.18 | $-0.52 | $-0.75 | $-2.70 | $-1.27 | $-0.67 | $-1.67 | $-0.89 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $5.1M | $11.2M | $11.2M | $10.3M | $12.0M | $16.1M | $17.9M | $18.0M | $19.9M | $26.6M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -82.87% |
| Rentabilidad sobre capital invertido | -92.78% |
| Rentabilidad sobre activos | -68.60% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.07 |
| Ratio corriente | 4.04 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -8.58 |
Ratios Clave (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -147.42 | -107.83 | -7.20 | -6.52 | -17.05 | -5.43 | -4.17 | -6.74 | -2.21 | -0.84 |
| P/VC | -273.55 | 4.95 | 5.42 | 2.52 | 5.33 | 2.05 | 1.89 | 5.31 | 2.90 | 1.76 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 18766.67 | 909.04 | 303.90 | 1306.23 | 6652.75 | 829.46 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | -111163.6% | -16106.6% | -6938.8% | -19187.7% | -304535.7% | -61738.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | -109990.9% | -16762.4% | -7299.2% | -19360.0% | -300585.7% | -91866.0% |